Daniel Mahony

Daniel joined Novo Holdings in 2024 as a Senior Partner in Growth Investments.

Daniel has 25+ years of global healthcare investment experience covering biotechnology, medical technology and healthcare services. In 2007, he co-founded the healthcare business unit at Polar Capital in London, growing it to over $4 billion in assets under management. Daniel was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto. He currently chairs the UK BioIndustry Association, is a Non-Executive Director of the Wellcome Sanger Institute in Cambridge, and was in 2022 appointed as the UK Government’s Life Sciences Envoy.

Daniel received his PhD in Development Biology from the University of Cambridge and his BA in Biochemistry from the University of Oxford.